CC
TEVA icon

Centiva Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Centiva Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,000
Closed -$4.68M – 2017
2025
Q4 		$4.68M Buy
+150,000
New +$3.7M 0.04% 266
2023
Q2 		– Sell
-9,000
Closed -$79.7K – 1993
2023
Q1 		$79.7K Buy
+9,000
New +$89K ﹤0.01% 1361

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Centiva Capital's TEVA Position: Q3 2025 in Review

Centiva Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 84,187 shares — an estimated $1.41M sold.

Centiva Capital first reported a position in TEVA in Q2 2022 and held it in 8 quarters. The position peaked at $1.41M in Q2 2025. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Centiva Capital reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 84,187 Teva Pharmaceuticals shares in Q3 2025, an estimated $1.41M.
  • Centiva Capital first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Centiva Capital's Teva Pharmaceuticals position peaked at $1.41M in Q2 2025.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.